<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04146402</url>
  </required_header>
  <id_info>
    <org_study_id>SCT-I10A-B301</org_study_id>
    <nct_id>NCT04146402</nct_id>
  </id_info>
  <brief_title>SCT-I10A Plus Standard Chemotherapy in First-line Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma</brief_title>
  <official_title>SCT-I10A Combined With Standard Chemotherapy Versus Placebo Combined With Standard Chemotherapy in First-line Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC): A Phase III, Multicenter, Randomized, Double-blinded Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sinocelltech Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sinocelltech Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the efficacy and safety of SCT-I10A plus standard&#xD;
      chemotherapy for Recurrent/ Metastatic Head and Neck Squamous cell Carcinoma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase III, multicenter, randomized, double-blinded trial designed to evaluate&#xD;
      Overall survival (OS) of SCT-I10A combined with standard chemotherapy in patients living with&#xD;
      Recurrent/ Metastatic Head and Neck Squamous cell Carcinoma&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 31, 2019</start_date>
  <completion_date type="Anticipated">July 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 29, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
    <description>OS is defined as time from first dose of SCT-I10A until the date of death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>1 year</time_frame>
    <description>PFS is defined as the time from first dose of SCT-I10A until the date of first documentation of progression or date of death, whichever occurs first,according to RECIST v1.1 criter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>1 year</time_frame>
    <description>ORR is defined as proportion of patients achieving complete response (CR) or partial response (PR) according to RECIST v1.1 during trial treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>SCT-I10A + Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SCT-I10A, 200 mg intravenous (IV) on Day 1 of each 3-week cycle. Chemotherapy: cisplatin+5-FU</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo, 200 mg intravenous (IV) on Day 1 of each 3-week cycle. Chemotherapy: cisplatin+5-FU</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SCT-I10A+chemo</intervention_name>
    <description>SCT-I10A, 200 mg intravenous (IV) on Day 1 of each 3-week cycle Standard chemotherapy: Cisplatin+5-FU</description>
    <arm_group_label>SCT-I10A + Chemotherapy</arm_group_label>
    <other_name>SCT-I10A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos+chemo</intervention_name>
    <description>Placebo, 200 mg intravenous (IV) on Day 1 of each 3-week cycle Standard chemotherapy: Cisplatin+5-FU</description>
    <arm_group_label>Placebo + Chemotherapy</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Voluntarily participate in this clinical trial and sign an informed consent form;&#xD;
&#xD;
          2. Male or female, age ≥ 18 years old;&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;&#xD;
&#xD;
          4. Has histologically- or cytologically-confirmed recurrent or metastatic (disseminated)&#xD;
             head and neck squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and&#xD;
             larynx;&#xD;
&#xD;
          5. Is considered incurable by local therapies;&#xD;
&#xD;
          6. Have measurable disease based on RECIST1.1. tumor lesions, situated in a previously&#xD;
             irradiated area are considered measurable if progression has been demonstrated in such&#xD;
             lesion after 3 months of radiotherapy;&#xD;
&#xD;
          7. Have provided tissue for PD-L1 biomarker analysis&#xD;
&#xD;
          8. The estimated survival period is ≥ 3 months;&#xD;
&#xD;
          9. Laboratory inspection:&#xD;
&#xD;
             Blood routine: neutrophils ≥1.5×l09/L, platelets≥75×109/L, hemoglobin≥80g/L; Liver&#xD;
             function: alanine aminotransferase (ALT) and aspartate aminotransferase (AST), ALT and&#xD;
             AST ≤ upper limit of normal value × 3 for liver metastasis, ALT and AST ≤ upper limit&#xD;
             of normal value for liver metastases × 5; total bilirubin ( TBIL) ≤ upper limit of&#xD;
             normal value × 1.5; Renal function: creatinine (Cr) ≤ normal upper limit × 1.5;&#xD;
             Coagulation: Activated Partial Thromboplastin Time (aPTT), International Normalized&#xD;
             Ratio (INR), Prothrombin Time (PT) ≤1.5xULN Echocardiogram: LVEF≥50%&#xD;
&#xD;
         10. Subjects should agree to use an adequate method of contraception starting with the&#xD;
             first dose of study medication through 6 months after the last dose of study therapy.&#xD;
             Female subjects of childbearing potential should have a negative blood pregnancy test&#xD;
             within 7 days prior to receiving the first dose of study medication, and should be&#xD;
             non-breastfeeding;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Disease is suitable for local therapy administered with curative intent&#xD;
&#xD;
          2. Has received systemic chemotherapy, except being part of the multimodality treatment&#xD;
             for local advanced HNSCC (the chemotherapy should be ended≥6 months prior to first&#xD;
             dose of study treatment)&#xD;
&#xD;
          3. Has progressed within 6 months after multimodality treatment for local advanced HNSCC&#xD;
&#xD;
          4. Prior therapy with an anti-PD-1 or anti-PD1-L1 or -L2 therapy, or anti-CD137, or&#xD;
             anti-CTLA-4 therapy&#xD;
&#xD;
          5. Diagnosed and/or treated additional malignancy within 5 years of randomization, with&#xD;
             the exception of curatively-treated basal cell or squamous cell carcinoma of the skin,&#xD;
             and/or curatively-resected in situ cervical cancers;&#xD;
&#xD;
          6. Has received cetuximab within 6 months prior to first dose of study treatment&#xD;
&#xD;
          7. NCI CTCAE v5.0 Grading of Peripheral Neuropathy≥2;&#xD;
&#xD;
          8. Active central nervous system (CNS) metastases and/or carcinomatous meningitis;&#xD;
             subjects with previous treated brain metastases may participate provided they are&#xD;
             stable for at least 2 weeks prior to the first dose of study medication, have no&#xD;
             evidence of new or enlarging brain metastases, and are not using steroids for at least&#xD;
             14 days prior to trial treatment. Subjects with asymptomatic BM (without neurological&#xD;
             symptoms, not using steroids, tumor lesions≤1.5cm) may participate in condition that&#xD;
             the tumor lesion should be regularly evaluated using identical imaging modality for&#xD;
             each assessment, either MRI or CT scans;&#xD;
&#xD;
          9. At the time of enrollment, patients still had ≥2 toxic side effects (except for hair&#xD;
             loss, hearing loss, tinnitus, dry mouth or platinum-induced grade 2 neurotoxicity)&#xD;
             caused by previous anti-tumor treatment;&#xD;
&#xD;
         10. Has known serious allergic reaction to study medication or any component of the&#xD;
             product, and has known serious allergic reaction to other monoclonal antibodies (NCI&#xD;
             CTCAE v5.0≥3);&#xD;
&#xD;
         11. Has received anti-tumor therapy, including chemotherapy, hormonal therapy,&#xD;
             immunotherapy, radiotherapy, and etc. within 4 weeks of the first dose of treatment,&#xD;
             except palliative radiotherapy for bone pain;&#xD;
&#xD;
         12. Has received any Chinese traditional medicine for anti-cancer purpose within 1 week of&#xD;
             the first dose of treatment;&#xD;
&#xD;
         13. Has undergone important surgery within 4 weeks prior to first dose of treatment or has&#xD;
             scheduled an important surgery during the study;&#xD;
&#xD;
         14. Has received immunosuppressive drugs during the study or within 2 weeks prior to first&#xD;
             dose of treatment, except for the following situations:&#xD;
&#xD;
             Intranasal, inhaled, topical corticosteroids (e.g. intra-articular injections);&#xD;
             Physiological dose for systemic prednisolone (≤10mg/d or equivalent); Short-term&#xD;
             administration (≤7days) of corticosteroids for prophylaxis or treatment against&#xD;
             non-autoimmune allergic disease&#xD;
&#xD;
         15. Has known active, and/ or history of autoimmune disease (systemic lupus erythematous,&#xD;
             rheumatoid arthritis, inflammatory bowel disease, AITD, multiple sclerosis,&#xD;
             vasculitis, glomerulonephritis), and is likely to get a recurrence, or is at high-risk&#xD;
             (organ-transplanted patients need immunotherapy), except those with stable type 1 DM&#xD;
             after fixed dose of insulin administration , or those with autoimmune hypothyroidism&#xD;
             only require HRT, or those with skin disorders that does not require systemic&#xD;
             treatment (e.g. eczema, rash &lt;10% BSA, psoriasis without symptoms around eyes)&#xD;
&#xD;
         16. Has known interstitial lung disease, such as interstitial pneumonia, pulmonary&#xD;
             fibrosis, except asymptomatic drug-induced pneumonitis or radiation pneumonitis&#xD;
&#xD;
         17. Has a known history of HIV&#xD;
&#xD;
         18. Has known active Hepatitis B (e.g. HBsAg reactive) or Hepatitis C(e.g. HCV RNA&#xD;
             [quantitative] is detected)&#xD;
&#xD;
         19. has uncontrolled active infections within 2 weeks before enrollment&#xD;
&#xD;
         20. Has received a live vaccine within 4 weeks prior to first dose of study treatment,&#xD;
             except&#xD;
&#xD;
         21. Is with clinical symptoms, required clinical intervention or stable time less than 4&#xD;
             weeks of serous cavity effusion (such as pleural effusion and ascites);&#xD;
&#xD;
         22. Has severe conditions, including NYHA III heart failure, IHD, history of MI within 3&#xD;
             months prior to first dose of study treatment, poorly controlled DM (FBS≥10mmol/L) or&#xD;
             poorly controlled hypertension (SBP≥160mmHg and/ or DBP≥100mmHg)&#xD;
&#xD;
         23. Has known psychiatric or substance abuse disorders that would interfere with&#xD;
             cooperation with the requirements of the trial&#xD;
&#xD;
         24. Is currently participating in other clinical trials, or has participated in a study of&#xD;
             an investigational agent and received study therapy, or used an investigational&#xD;
             device, any of whose end date is within 4 weeks prior to the first dose of study&#xD;
             medication&#xD;
&#xD;
         25. has alcohol or drug addiction;&#xD;
&#xD;
         26. Subjects who are considered unsuitable for participating in this study for various&#xD;
             reasons at the discretion of the investigator，such as inability to comply with study&#xD;
             and/or follow-up procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuankai Shi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yan Wang, MD</last_name>
    <phone>15201286305</phone>
    <email>SCT-CT@sinocelltech.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Third Affiliated Hospital Of Qiqihar Medical University</name>
      <address>
        <city>Qiqihar</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhongling Xu, MD</last_name>
      <phone>15845688067</phone>
      <email>xuzhongling2009@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 29, 2019</study_first_submitted>
  <study_first_submitted_qc>October 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2019</study_first_posted>
  <last_update_submitted>February 3, 2020</last_update_submitted>
  <last_update_submitted_qc>February 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

